Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for InvestorsZacks Investment Research • Friday
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?Zacks Investment Research • Thursday
Recursion Pharmaceuticals (RXRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • Wednesday
Why Investors Need to Take Advantage of These 2 Medical Stocks NowZacks Investment Research • Tuesday
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to ConsiderZacks Investment Research • Monday
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3GlobeNewsWire • Monday
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth KnowingZacks Investment Research • 10/20/26
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their CollaborationGlobeNewsWire • 10/15/26
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common StockGlobeNewsWire • 10/15/26
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership MilestoneGlobeNewsWire • 10/15/26
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to NoteZacks Investment Research • 10/12/26
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research • 10/06/26
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?Zacks Investment Research • 09/24/26
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation ModelBusiness Wire • 09/21/26
Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley ConferenceMarketBeat • 09/21/26
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to KnowZacks Investment Research • 09/16/26
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market TodayZacks Investment Research • 09/10/26
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?Zacks Investment Research • 09/04/26
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?Zacks Investment Research • 09/03/26
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes PharmaZacks Investment Research • 08/17/26
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline UpdatesMarketBeat • 08/17/26
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference TranscriptSeeking Alpha • 08/11/26